Low dose intra-arterial streptokinase and acylated plasminogen-streptokinase activator complex: a retrospective review of two thrombolytic regimes in recent peripheral arterial ischaemia.
Thrombolytic therapy was used for 57 patients with acute and sub-acute lower limb arterial ischaemia. In the first 34 patients a new thrombolytic agent, acylated plasminogen-streptokinase complex (BRL 26921) was assessed. Following this, 23 patients received low dose intra-arterial streptokinase. The two thrombolytic regimes have been analysed retrospectively. There were differences observed between the two groups in the type of patients treated and in the severity of limb ischaemia. Of the patients receiving BRL 26921, five (15%) had complete, and three (9%) partial lysis of the occluding thrombus. Serious bleeding occurred in six (18%) and minor bleeding in ten (29%) patients. After 30 days, twelve patients (35%) had limb salvage and eleven (32%) had died. Fifteen patients (65%) receiving intra-arterial streptokinase had lysis of the occluding thrombus. Minor bleeding was observed in three patients (13%). After 30 days, 15 (65%) had limb salvage and three (13%) had died. Patients receiving BRL 26921 had a significantly greater reduction in plasma fibrinogen and plasminogen concentrations during treatment which may have accounted for the bleeding complications. At the dose used, BRL 26921 had no demonstrable fibrinogen sparing effect. Improved lysis rates with fewer bleeding complications might be achieved by reducing the dose of BRL 26921. Low dose intra-arterial streptokinase has been confirmed as a safe, effective method of thrombolysis in recent peripheral arterial ischaemia.
Earnshaw
J J
JJ
Vascular Surgery, University Hospital, Nottingham, U.K.
Westby
J C
JC
Makin
G S
GS
Hopkinson
B R
BR
D000368:Aged; D016255:Anistreplase; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007261:Infusions, Intra-Arterial; D007275:Injections, Intravenous; D007866:Leg / Q000098:blood supply*; D008297:Male; D010958:Plasminogen / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D012189:Retrospective Studies; D013300:Streptokinase / Q000008:administration & dosage* / Q000009:adverse effects
D005343:Fibrinolytic Agents; D016255:Anistreplase; D005340:Fibrinogen; D010958:Plasminogen; D013300:Streptokinase